Key result
Intrarenal zyxin overexpression reduces renal fibrotic markers ~40% and attenuates tubulointerstitial injury in mice.
Why the study?
The molecular mechanisms underlying tubulointerstitial fibrosis and inflammation in hypertensive nephropathy remain elusive, and the specific role of the focal adhesion protein zyxin in hypertensive nephropathy-induced tubulointerstitial injury was undefined.
Does intrarenal zyxin overexpression improve renal function and attenuate tubulointerstitial injury in a murine model of hypertensive nephropathy?
Does intrarenal zyxin overexpression improve renal function and attenuate tubulointerstitial injury in a murine model of hypertensive nephropathy?
Preclinical findings demonstrate that zyxin protects against hypertensive nephropathy-induced tubulointerstitial fibrosis and inflammation independently of blood pressure by restraining FAK/Skp2–CDK8/YAP signaling.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for zyxin-targeted therapy in hypertensive nephropathy; leaves open translation to human disease.
Background Tubulointerstitial fibrosis and inflammation are hallmark pathological features of hypertensive nephropathy (HN), yet the underlying molecular mechanisms remain elusive. Zyxin, a focal adhesion protein, has been implicated in hypertension-related pathologies, but its specific role in HN-induced tubulointerstitial injury remains undefined. Methods An HN murine model was established via a multi‑hit DOCA/Ang II + uninephrectomy + high salt approach. Intrarenal zyxin was overexpressed using adeno-associated virus. In vitro, HK-2 cells were stimulated with Ang II, and zyxin levels were modulated via lentiviral transduction. Renal function, inflammation, and fibrosis were evaluated through biochemical assays and molecular signaling analysis. Results Zyxin was significantly downregulated in the renal tubules of HN mice and Ang II-treated HK-2 cells. Zyxin overexpression significantly improved renal function and attenuated tubulointerstitial injury, with a representative reduction of approximately 40% in the expression of fibrotic markers. These protective effects occurred independently of blood pressure changes. Mechanistically, zyxin reduction is linked to Ang II-induced calpain activation. The resulting zyxin depletion potentially disinhibits the FAK/Skp2 axis and enhances CDK8/YAP signaling, which may contribute to renal inflammation and interstitial fibrosis. Conclusions These findings support a model in which zyxin acts as a protective factor in the renal tubules during HN, suggesting its potential as a novel therapeutic target.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied Hypertensive nephropathy. Intrarenal zyxin overexpression (via adeno-associated virus in vivo and lentiviral transduction in vitro) was evaluated on Renal function, tubulointerstitial injury, and expression of fibrotic markers. Intrarenal zyxin overexpression improved renal function and attenuated tubulointerstitial injury in mice, reducing fibrotic marker expression by approximately 40% independently of blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: